Bioxodes obtains authorization to launch phase I trial of its antithrombotic drug, Ir-CPI, in healthy male volunteers

October 15th 2019

Bioxodes, a clinical stage biotech company developing a potential best-in-class antithrombotic agent for acute cardiovascular setting, announces today that the Belgian Federal Agency for Medicines and Healthy Products (FAMHP), together with the designated Ethics Committee, have authorized the initiation of a double blind, placebo controlled, single ascending dose phase I trial with its candidate, Ir-CPI, in healthy male volunteers.

Please find the press release here.